Home /

FDF / DRUG PRODUCTS in Europe

End-to-End Pharma CDMO

Germany Europe

FDF / DRUG PRODUCTS in Europe

End-to-End Pharma CDMO

FDF / DRUG PRODUCTS  in Europe

About the plant

PSM GmbH is a family-­run German company that oper­ates as a Contract Development and Manu­facturing Organi­zation (CDMO) in the pharma­ceutical indu­stry, located in Schiffweiler in the state of Saarland. With our new state-­of-the-art facility, we are proud to be one of the first European CDMOs to have passed the inspec­tion by the local authorities under the new EU GMP Annex 1.

As an end-to-end CDMO, we provide services for the entire imple­mentation process and life­cycle of your drug, from clinical phases to commer­cial GMP manu­fac­turing. Our portfolio in­cludes method and process development, in-house analytical services, aseptic fill and finish services, visual inspection with CCIT, secondary packaging with seriali­zation, as well as GMP storage and GDP transport.

Our facility is designed to process all common ready-­to-use primary pack­aging con­tainers, in­cluding pre-­fillable syringes (PFS) up to 10 mL, vials up to 100 mL, and cart­ridges up to 10 mL, made of glass or polymer.

This flexibility enables us to offer fill and finish services for biopharmaceutical drugs, biosimilars, small molecules and diluents (e.g. WFI). Our current processes can accommodate batch sizes of up to 600 liters.

 

For very high-­value drugs, we use the most sophisti­cated fill and finish technolo­gies to minimize product loss through­out the entire pro­cessing cycle for batch sizes of up to 100 liters.


Certifications

Activity
  • Injectables, Terminal sterilization, Fill&Finish, Small volume vials, Large volume vials / Bottles, PFS (Prefilled Syringes), Cartridges, Flexible bags / Infusion systems, FDF / DRUG PRODUCTS manufacturing

Features
  • Uses: Investigational, Commercial (Phase IV), Preclinical, Phase I, Phase II, Phase III, Human
  • Toxicity (OEB classification): 1 / low-hazard (PDE > 5,000 µg/day), 2 (PDE = 1,000 - 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)
  • Controlled substance: N/A
  • BSL: 1
  • Therapeutic areas: N/A
  • Markets: FDA (USA), EMA (EU), PMDA (Japan), MHRA (UK), TGA (Australia), NMPA (China)

Batch Size / Reactor
  • Small, Medium, Large

Services
  • Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging, Logistics, R&D, QbD (Quality by Design), Process development, Process validation, Lyophilization cycle development, Stability studies execution, ICH Stability studies, Comparability studies, Tech transfer, Pilot plant, Lyophilization, Engineering batches, Scale-up, Pilot batches, Registration batches, Batch records, Analytical methods development, Analytical methods validation, Release testing of raw materials, Release testing of product, Bioanalysis, Analytical methods transfer, QP in house, Batch certification / release, GMP documentation, Parametric release, Primary packaging, Secondary packaging, Labeling, Serialization, Storage, Distribution, GDP

Contact us

If you have any questions or suggestions, click here. We will be happy to assist you.

Want to see all the information?

Unleash the full power of MAI CDMO

Register for free

Salvat
Mabion
Lannett
ReigJofre
Sylentis
Pharmaron